Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients.

Purpose: To evaluate the safety and efficacy of bevacizumab and weekly docetaxel as first- or second-line therapy in patients with metastatic breast cancer (MBC).

Patients And Methods: Twenty-seven MBC patients received i.v.